

# Does your patient's allergic rhinitis treatment have what it takes?

## Dymista® Delivers:

### > Proven superiority over FP or AZE monotherapy in relieving moderate-severe AR symptoms\*<sup>1-3</sup>

\*Superior improvement in rTNSS over 14 days with Dymista® 125 /50 vs. FP (P = 0.001), AZE (P < 0.001) and placebo (P < 0.001) (meta-analysis, 3 phase III, randomised, placebo controlled studies, n = 3,398)<sup>2</sup>



#### Speed

Clinically relevant onset of action within **30 minutes**<sup>2,4</sup>



#### Strength

**Twice the allergic rhinitis symptom relief** vs. FP or AZE monotherapy<sup>1,3</sup>

<sup>1</sup>Placebo subtracted rTNSS compared to FP (P = 0.0013) and AZE (P = 0.0004) at day 14, post-hoc analysis (n = 610)



#### Sustainability

**Sustained nasal symptom relief** through 52 weeks of treatment<sup>+5</sup>

<sup>±</sup>Change from baseline in rTNSS score over 52 weeks (n = 388, Dymista® 125/50 vs. FP was P = 0.0048 at 28 weeks and P = 0.0642 at 52 weeks NS)




# Dymista® 125/50

azelastine hydrochloride/fluticasone propionate

# Dymista® Delivers:

## > Relief from a full range of nasal and ocular symptoms for moderate-severe AR patients\*<sup>1,2,4</sup>

\*Successful reductions in rTNSS and rTOSS in efficacy and safety studies of Dymista® 125/50



Dymista® 125/50 is indicated for the symptomatic treatment of moderate to severe allergic rhinitis and rhino-conjunctivitis in adults and children 12 years and older where use of a combination (intranasal antihistamine and glucocorticoid) is appropriate<sup>4</sup>

**PBS Information:** This product is not listed on the PBS.

Please review Product Information before prescribing. Full Product Information is available at [www.medicines.org.au/files/gopdymis.pdf](http://www.medicines.org.au/files/gopdymis.pdf) or on request by calling 1800 314 527.

**Dymista® 125/50** (azelastine hydrochloride 125µg / fluticasone propionate 50µg) nasal spray 17mL, 120 sprays). **Indications:** Symptomatic treatment of moderate to severe allergic rhinitis and rhino-conjunctivitis in adults and children 12 years and older where use of a combination (intranasal antihistamine and glucocorticoid) is appropriate. **Dosage:** Adults and adolescents (≥ 12 yrs): One spray in each nostril twice daily. **Contraindications:** Hypersensitivity to the active substance(s) or excipients. **Precautions:** Pregnancy (Cat B3) and lactation; operating machinery or driving motor vehicle; use with alcohol or other CNS depressants, somnolence; patients with recent nasal ulcers, surgery or injury to nose or mouth; patients susceptible to candida infections (e.g. diabetics); visual disturbance, glaucoma and/or cataracts; HPA axis effect/suppression, adrenal function impairment; tuberculosis or untreated respiratory infection; children and adolescents (< 12yrs); severe hepatic and renal impairment. **Interactions:** Cytochrome P450 3A4 inhibitors (potential increase fluticasone propionate exposure) eg: ritonavir, ketoconazole, cimetidine; CNS depressants. **Adverse Effects:** Common: headache, dysgeusia, unpleasant smell; Uncommon: epistaxis, nasal discomfort, sneezing, nasal dryness, cough, dry throat and irritation; Very rare: somnolence; nasal septal perforation; hypersensitivity including anaphylactic reactions, angioedema and bronchospasm. **Min PI Updated:** 19 Jun 2018.

**Abbreviations:** AH, antihistamine; AZE, azelastine; FP, fluticasone propionate; INCS, intranasal corticosteroid; NS, Not significant; rTSS, reflective total of 7 symptom scores; rTNSS, reflective total nasal symptom score; rTOSS, reflective total ocular symptom score.

**References:** 1. Meltzer E, *et al.* Int Arch Allergy Immunol. 2013;161:369-77. 2. Carr W, *et al.* J Allergy Clin Immunol. 2012;129(5):1282-9. 3. Hampel FC, *et al.* Ann Allergy Asthma Immunol. 2010;105: 168-73. 4. Dymista® 125/50 Approved Product Information. 5. Price D, *et al.* J Investig Allergol Clin Immunol. 2013;23(7):495-503.

MYLAN® is a registered trade mark of Mylan Inc. DYMISTA® is a registered trade mark of Meda AB. Copyright© 2018 Mylan N.V. All rights reserved. Mylan Health Pty Ltd. Level 1, 30-34 Hickson Rd, Millers Point, NSW, 2000, Australia. ABN: 29 601 608 771. Call: 1800 314 527. DYM-2019-0054. Date of preparation: January 2019.

 Mylan®